{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003864198,0.002467448,0.00342452,0.0004077828,0.0004240242,0.00173038,0.001131061,0.002241338,0.005341908],"category_scores_gemma":[0.003271073,0.000933811,0.003972881,0.0004707353,0.001572924,0.002107309,0.0007905553,0.004412704,0.001100194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001521389,"about_ca_system_score_gemma":0.001193496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001339325,"about_ca_topic_score_gemma":0.002689162,"domain_scores_codex":[0.9983248,0.0009992654,0.00007390347,0.0002458246,0.0000915694,0.0002647072],"domain_scores_gemma":[0.9978074,0.0006955063,0.0004732285,0.0002221727,0.0001142158,0.0006875664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9913191,0.001695986,0.0006614439,0.0001732553,0.001079657,0.00002540676,0.00003991152,0.0003226841,0.0008929982,0.00005777186,0.0002849551,0.003446753],"study_design_scores_gemma":[0.9155979,0.07646539,0.004414513,0.00004079149,0.00167816,0.00004913462,0.00005660714,0.0006028629,0.0002545603,0.0002362266,0.0005730079,0.00003092815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922221,0.003546895,0.0004663352,0.0007316092,0.0005181865,0.0006323385,0.0006910554,0.00004938129,0.00114205],"genre_scores_gemma":[0.9907951,0.001767138,0.000780492,0.000913752,0.0004957704,0.0009425954,0.001574127,0.00003108838,0.002699999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005341908,"threshold_uncertainty_score":0.02043611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0391025579184239,"score_gpt":0.3926124320995352,"score_spread":0.3535098741811113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}